传统 Medicare 与 Medicare Advantage 中骨质疏松检测与治疗率均偏低
本研究利用 2017-2019 年全国代表性 20% 样本,比较传统 Medicare(TM)与 Medicare Advantage(MA)女性参保者的骨质疏松管理。MA 参保者的骨密度检测率和骨质疏松药物起始率均高于 TM,且在脆性骨折后更可能被处方药物治疗,但两组检测与治疗起始率总体均偏低。
要点
- MA 参保者骨密度检测率未调整 22.0% vs TM 19.8%(P < 0.001),调整后高 0.8 个百分点(P < 0.001)。
- MA 参保者骨质疏松药物起始率未调整 24.9% vs TM 20.3%(P < 0.001),调整后高 4.0 个百分点(P < 0.001)。
- 脆性骨折后 MA 参保者接受药物治疗比例 28.7% vs TM 21.1%(P < 0.001),调整后高 5.9 个百分点(P < 0.001)。
核心结论
- TM 与 MA 参保者的骨质疏松检测与治疗起始率总体均偏低,MA 较 TM 有所改善。
研究设计与样本
- 横断面研究,使用 2017-2019 年全国代表性 20% 的 TM 理赔数据和 MA 就诊记录。
- 纳入 2,994,203 名女性 TM 受益人和 1,924,132 名 MA 参保者,暴露为 MA 参保。
主要发现
- MA 参保者骨密度检测率未调整 22.0% vs TM 19.8%(P < 0.001),调整后高 0.8 个百分点(P < 0.001)。
- MA 参保者骨质疏松药物起始率未调整 24.9% vs TM 20.3%(P < 0.001),调整后高 4.0 个百分点(P < 0.001)。
- 脆性骨折后 MA 参保者接受药物治疗比例 28.7% vs TM 21.1%(P < 0.001),调整后高 5.9 个百分点(P < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Little is known regarding osteoporosis management between Traditional Medicare (TM) and Medicare Advantage (MA). MA beneficiaries had higher rates of osteoporosis testing and higher rates of osteoporosis drug treatment initiation rates. Following an osteoporotic fragility fracture, MA beneficiaries were more likely to be prescribed osteoporosis treatment. While osteoporosis testing and treatment initiation rates are low in both TM and MA, rates tended to be higher in MA. PURPOSE: Osteoporosis represents a substantial clinical challenge in the United States, particularly for older women, and requires effective care coordination. Medicare Advantage (MA) plans have financial incentives in the form of star ratings to improve osteoporosis testing and treatment. The objective of this study was to compare osteoporosis management practices between Traditional Medicare (TM) beneficiaries and MA female enrollees. METHODS: We conducted a cross-sectional study using a nationally representative 20% sample of 2017-2019 TM claims and MA encounter records. We identified 2,994,203 female TM beneficiaries and 1,924,132 MA enrollees. The exposure was enrollment in MA. The primary outcomes were the rates of guideline-recommended bone mineral density (BMD) testing and osteoporosis drug initiation following a new osteoporosis diagnosis and after a new osteoporotic fragility fracture. RESULTS: MA beneficiaries had higher unadjusted (22.0% vs. 19.8% in TM; P < 0.001) and adjusted rates (0.8 percentage points [p.p.] higher; P < 0.001) of BMD testing. Osteoporosis drug treatment initiation rates were higher in the MA cohort, both unadjusted (24.9% vs. 20.3% in TM; P < 0.001) and adjusted (4.0 p.p. higher; P < 0.001). Following an osteoporotic fragility fracture, MA beneficiaries were more likely to be prescribed pharmacologic treatment (28.7% vs. 21.1% in TM; P < 0.001), with an adjusted increase of 5.9 p.p (P < 0.001). CONCLUSION: Overall osteoporosis testing and treatment initiation rates in both TM and MA enrollees were low, with improved rates in MA compared to TM.
引用
- Azad TD, Wu RJ, Anderson KE, et al. Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage. Osteoporos Int. 2024. PMID: 39570337. doi:10.1007/s00198-024-07318-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。